Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

The USPTO-FDA Collaboration: Laying the Foundation for the Life Sciences Industry and Beyond

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

In 2021, President Biden called for action “to help ensure the patent system, while incentivizing innovation, does not also unjustifiably delay generic drug and biosimilar competition beyond that reasonably contemplated by applicable law.” In response, the USPTO and the FDA have begun an unprecedented collaboration that the USPTO believes will “strengthen our patent system for all technologies.”

The USPTO-FDA Collaboration: A Discussion Of Recent Activity And Possible Next Steps 

In 2021, President Biden called for action “to help ensure the patent system, while incentivizing innovation, does not also unjustifiably delay generic drug and biosimilar competition beyond that reasonably contemplated by applicable law.” In response, the USPTO and the FDA have begun an unprecedented collaboration that the USPTO believes will “strengthen our patent system for all technologies.” This webinar will explore the first steps of that collaboration and possible next steps, including:<ul><li>The USPTO’s notice on duties of disclosure and reasonable inquiry, particularly with respect to statements made to the FDA.</li><li>The FDA’s (and some senators’) concerns about continuation practice and the USPTO’s request for comments on that issue.</li><li>The role of the PTAB in the collaboration, including the interplay between post grant proceedings at the PTAB and Orange-book listed patents and biologic patents.</li></ul>The webinar will include a diverse panel of stakeholders, including Active Vice Chief Administrative Patent Judge Linda Horner and Deputy Commissioner Bob Bahr of the USPTO and former FDA Chief Counsel Stacy Amin.This session is hosted by the Berkeley Center for Law & Technology (BCLT). We hope to see you there!<h5>Speakers</h5><ul><li>Linda Horner – Acting Vice Chief Administrative Patent Judge, USPTO</li><li>Bob Bahr – Deputy Commissioner, USPTO</li><li>Mehran Arjomand – Partner, Morrison Foerster</li><li>Stacy Amin – Former FDA Chief Counsel, Partner, Morrison Foerster</li><li>Dr. Jean Nguyen – Associate, Morrison Foerster</li></ul><hr>

Sign Up

Mehran Arjomand is chair of the firm's Patent Trial and Appeal Board Practice and heads the firm's technology patent practice. Mr. Arjomand began his legal career as a litigator. After five years, he joined Morrison & Foerster, where he developed a strong foundation in USPTO prosecution and procedure. With his combined litigation and prosecution experience, he is able to counsel clients on end-to-end strategies—from patent creation to patent challenges.In his role as chair of the firm's Inter Partes Review and Post Grant Practice and previously the firm's Patent Reexamination Group, he has overseen hundreds of post-grant proceedings. He not only initiates post-grant proceedings for petitioners but also defends patent owners in such proceedings, from filing to appeal. Mr. Arjomand also regularly provides strategic guidance for and management of post-grant proceedings co-pending with litigation.Representative completed post-grant matters include the following.<ul><li>PGR2017-00009 Successfully represented patent owner PhishMe in PGR. The USPTO denied the petition based on a PGR eligibility argument.</li></ul><ul><li>PGR2017-00001, IPR2017-00123 Defendant settled with petitioner Yuneec shortly after filing of petitions.</li></ul><ul><li>IPR2014-01266, -01313 Defended patent owner HML against two inter partes reviews by different parties, resulting in claim survival or petition denial. </li></ul><ul><li>IPR2013-00593, -00594, -00597, -00598  Represented petitioner Yamaha in a series of inter partes reviews in which all pending claims were found unpatentable in final written decisions by the USPTO.</li></ul><ul><li>IPR2013-00149 Shortly after inter partes reviews became available, filed and led this review for petitioner Wavelock Advanced Technology. All pending claims were subsequently cancelled by patent owner.</li></ul><ul><li>Reexamination Control No. 95/001,734 Prepared and led inter partes reexamination of patent asserted against Yahoo! All pending claims were cancelled.</li></ul><ul><li>Reexamination Control No. 95/001,381 Successfully defended patent owner through appeal. Federal Circuit issued a precedential decision,  805 F.3d 1350, in favor of Netlist.</li></ul><ul><li>Reexamination Control No. 95/000,293 Prepared and oversaw this inter partes reexamination of a patent asserted against EchoStar. All pending claims were cancelled or amended. The matter settled favorably for EchoStar.</li></ul><div>In addition to his practice relating to adversarial PTO proceedings, Mr. Arjomand regularly prosecutes patent applications. He concentrates his prosecution work on consumer electronics, semiconductor processing, and automotive technologies. Mr. Arjomand works closely with clients in these technology sectors to develop and manage their patent portfolios. Additionally, Mr. Arjomand lived in Japan in 2008, where he worked extensively with Japanese technology companies to develop their global patent portfolios.Mr. Arjomand received his B.S. in mechanical engineering from the University of California, Berkeley in 1991, where he graduated with high honors. He obtained his J.D. from Berkeley Law in 1995. Mr. Arjomand is admitted to practice in California and is registered to practice before the USPTO.</div>

Mehran Arjomand

Partner

A former lead engineer at the NASA Jet Propulsion Laboratory, Dr. Nguyen focuses her practice on domestic and international patent prosecution. She is a founder and co-leader of the firm’s Life Sciences Data Analytics patent group. She applies her experience also from her doctoral studies and her work as a former research scholar to provide portfolio management and counseling, IP due diligence, and freedom-to-operate analyses. Dr. Nguyen also has experience drafting briefs and inter partes reviews (IPRs), analyzing prior art and patent infringement, working with experts, and handling disputes before the U.S. International Trade Commission (ITC) and the federal courts. Her clients include large domestic and international companies, early-stage startups, and universities.Dr. Nguyen’s knowledge spans a wide range of technology areas, including electronic devices, medical devices and health systems, semiconductor materials and fabrication, computer/device hardware, memory, optoelectronics, optics, nanotechnology, microelectromechanical systems (MEMs), electronic packaging, augmented/virtual reality systems, autonomous vehicles, smart glass, mechanical assemblies, and consumer products. Her experience also encompasses telecommunications and networks, integrated circuits and digital designs, quantum computing, computer software, and digital cameras.Prior to joining Morrison & Foerster, Dr. Nguyen was a lead engineer at the NASA Jet Propulsion Laboratory and a hardware engineer at Hewlett-Packard. She also worked as a research scholar at the Center for Quantum Devices, Georgia Tech Computer Aid Design Lab, and Berkeley Wireless Research Center, where her research involved collaborating with several companies and laboratories such as Raytheon, Cree, IBM, Intel, BAE Systems, Lockheed Martin, Sandia National Labs, U.S. Army Night Vision Labs, Naval Research Lab, Aerospace Corporation, Argonne National Lab, Lawrence Livermore National Lab, Los Alamos National Lab, L3 Communications, Boeing, General Electric, FLIR, Teledyne, and Rockwell Automation.Dr. Nguyen received her J.D. from Loyola Law School. She also received her Ph.D. in electrical engineering from Northwestern University, where she focused her studies on semiconductor materials and optoelectronic devices. She received her M.S. in computer science from the Georgia Institute of Technology, where she focused her studies on computer-aided design and quantum computing. Jean also received her B.S. degree in computer engineering from the University of Wisconsin at Madison with emphasis on integrated circuits and digital designs. She has authored over 40 technical publications, 50 conference proceedings, and three book chapters. She also holds three patents.Dr. Nguyen has served on several committees with the Los Angeles Intellectual Property Law Association (LAIPLA). She is registered to practice in California and before the United States Patent and Trademark Office.

The USPTO-FDA Collaboration: Laying the Foundation for the Life Sciences Industry and Beyond

15 Nov 2022 12:00 PM - 1:00 PM PST

Speakers